Sernova Awarded Europe’s Prestigious Horizon 2020 Grant to Fund Development of Cell-Based Hemophilia Therapeutic Product Into the Clinic

Distinguished European consortium awarded approximately $8.5 Million CAD by the European Commission via its Horizon 2020 Program to partner advanced cell based Factor VIII therapy in collaboration with Sernova and its Cell Pouch(TM) device technologies LONDON, ONTARIO – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, announced today that […]

Read More

Sernova Secures Commercial Rights To Proprietary Stem Cell Derived Technologies

UHN (University Health Network) agreement transitions Sernova to an integrated therapeutic cell regenerative medicine Company LONDON, ONTARIO – Sernova Corp. (TSX-V: SVA) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a […]

Read More

Sernova Corp. Announces Collaboration with Massachusetts General Hospital to Develop Novel Diabetes Treatment with Funding Support from JDRF

Collaboration Combines Sernova’s Cell Pouch™ and Massachusetts General Hospital’s Novel Immune Protection Technology LONDON, ONTARIO–(Marketwired – July 7, 2015) – Sernova Corp. (TSX VENTURE:SVA)(FRANKFURT:PSH), is pleased to announce a research collaboration with Massachusetts General Hospital, supported with funding from JDRF to develop a novel treatment for diabetes. Sernova and Dr. Mark Poznansky, M.D., Ph.D., Associate Professor […]

Read More

Sernova Receives Issued Patent in the United States for Its Cell Pouch™ and Therapeutic Cell Transplantation Technologies

Sernova’s cell transplantation and local immune protection patent families are secured and protected to maximize stakeholder value LONDON, ONTARIO–(Marketwired – April 23, 2015) – Sernova Corp. (TSX VENTURE:SVA), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued Sernova a patent that helps protect Sernova’s entire Cell Pouch System ™. This patent […]

Read More

Sernova Completes Oversubscribed Private Placement; Adds Management Depth With New CFO

VANCOUVER, BRITISH COLUMBIA–(Marketwired – May 15, 2015) – NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES – SERNOVA CORP. (the “Company”) (TSX VENTURE:SVA) announces that, further to its news release of May 8, 2015, it has completed a non-brokered private placement of 8,888,889 units (the “Units”) at $0.18 per unit for gross […]

Read More

Sernova is Awarded Patents in Multiple Countries for Cell Pouch™ and Therapeutic Cell Transplantation Technologies

LONDON, ONTARIO–(Marketwired – Feb. 12, 2015) – Sernova Corp. (TSX VENTURE:SVA), today announced that the Patent Offices in China, Israel, Singapore and New Zealand have issued Notices of Allowance and issued patents to Sernova for its patent application entitled “Methods and Devices for Cellular Transplantation.” These patents help protect Sernova’s entire Cell Pouch™ system, including the […]

Read More